CAPD Statement on the Introduction of the “Remedy Act”
Debra Barrett, Executive Director of the Coalition for Affordable Prescription Drugs, released the following statement today on the introduction of the “Remedy Act:”
“We applaud ongoing efforts in Congress to disrupt anti-competitive tactics used by drug manufacturers to delay timely competition. These tactics enable manufacturers to maintain monopoly pricing of the medicine Americans need and it is critical to address this in the effort to ensure access and affordability. The “Remedy Act,” introduced by Senators Cassidy and Durbin, would narrow the opportunity for “ever greening” patent protection thereby promoting a more competitive marketplace for generic and biosimilar drugs, and in turn, driving down prices at the pharmacy counter. We urge lawmakers to support measures like this that aim to enable market forces in the fight against the high prices set by drug companies.”